Introduction
Proximal tubule epithelial cells (PTEC) of the kidney are known to respond to and mediate the disease process in a wide range of kidney diseases [1] [2] [3] [4] . Many of the chemokines secreted by PTEC in the perturbed disease state, including transforming growth factor beta (TGF-β), RANTES, MCP-1 and IL-8, result in a pro-inflammatory phenotype within the interstitium of the kidney. This attracts lymphocytes, monocytes and macrophages which in turn contribute to the inflammatory phenotype by secreting a secondary wave of cytokines including IFN-γ, IFN-α and TNFα which further activate PTEC, along with inappropriate tissue damage [5] . Within this disease setting, PTEC have been reported to up-regulate a range of surface antigens (Ags) known to be important in immune modulation [6] [7] [8] . These include major histocompatibility class I and II Ags (MHC I and II), CD40, inducible T cell co-stimulator ligand (ICOS-L) and the inhibitory programmed death ligand 1 (PD-L1). The presence of these Ags suggests that PTEC can act as nonprofessional antigen-presenting cells (APC) and may both modulate immune responses and become targets of cytotoxic CD8 + T cells. This has stimulated research, using mouse models and allogeneic human studies, to determine the role PTEC play in immune modulation.
In the mouse, Würthrich's group demonstrated that these cells could act as APC and that PD-L1 expression resulted in CD4 + Th1 and Th2 suppression in the context of specific antigen [9] . This group then went on to show that PD-L1 partially protected PTEC from CD8 + cytotoxic cells [10] and that the inflammatory mediator TGF-β plays a role in enhancing such cytotoxic affects by modulating PD-L1 and CD40 expression [8] . Chen et al. [11] also demonstrated a role for PTEC as APC in CD4 + activation and that PD-L1 was able to modulate this response in the context of IL-2 production and CD69 expression. However, although these mouse studies enable dissection of the role of PTEC as APC, they may not accurately reflect what is happening in the human body. Initial work to translate this research to human biology by the Dutch group of Van Kooten using an anti-CD3/CD28 T-cell activation model demonstrated PD-L1-mediated inhibition of proliferation and cytokine secretion and ICOS-L-mediated up-regulation of IL-10 secretion [12] . Ding et al. [13] , using the transformed human kidney cell line HK-2, confirmed a role for PD-L1mediated inhibition of mitogen-activated Jurkat and human T cells. More recently, a report by Starke et al. [14] describes a role for PTEC PD-L1 in suppressing alloreactive human T-cell responses.
To discover if PTEC similarly modulate immune responses in the autologous human context, we analysed the interactions of peripheral blood mononuclear cells (PBMC) and purified T and B cells with autologous PTEC in the presence of stimuli which mimic immunological signalling.
Materials and methods

General reagents
Cytokines were obtained from R&D Systems (Minneapolis, MN, USA), mitogens and cell culture reagents from Sigma (St. Louis, MI, USA) and Invitrogen (Gaithersberg, MD, USA) and antibodies (Ab) from BD Biosciences (San Jose, CA, USA), Biolegend (San Diego, CA, USA), Abcam (Cambridge, MA, USA) and Jackson (West Grove, PA, USA).
Donor tissue and blood
Following ethics approval and informed consent, kidney tissue was obtained from the healthy portion of tumour nephrectomies. Blood was obtained from these same donors 3 to 6 months post-nephrectomy. PBMC were isolated by Ficoll-density gradient separation. B cells and CD4 + and CD8 + T cells were purified with Miltenyi Microbeads (Sydney, Australia) coupled to αCD19, αCD4 and αCD8, respectively, following the manufacturer's instructions.
Cell culture
Cortex tissue was dissected from macroscopically/microscopically normal portions of the kidney and processed for PTEC purification within 1 h. PTEC were purified following the method of Glynne and Evans [15] and cultured in defined media. Defined medium (DM) comprised a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 containing 15 mM HEPES buffer, L-glutamine and pyridoxine hydrochloride. The medium was supplemented with epidermal growth factor (10 ng/mL), insulin (10 mg/mL), transferrin (5 mg/mL), selenium (5 ng/mL), hydrocortisone (36 ng/mL), triiodothyronine (4 pg/mL), penicillin (50 U/mL), streptomycin (50 mg/ mL) and amphoterecin B (0.125 mg/mL). Cell stocks were frozen at passage 1 (P1), and all PTEC were used in final experiments between P2 and P3. PTEC were characterized on the basis of (i) strong staining for cytokeratin-18, (ii) strong staining for alkaline phosphatase activity using the naphtal AS-MX method and (iii) characteristic cobblestone morphology.
Activation of PTEC P2 PTEC were cultured in DM until 70% confluence and exposed to IFN-γ (100 ng/mL), IFN-α (100 units/mL), TNF-α (20 ng/mL) or TGF-β (20 ng/mL) for 36 h. Cells were gently detached with TrypLE, neutralized immediately with trypsin inhibitor, washed once in DM and re-suspended in phosphate-buffered saline (PBS) containing 0.02% sodium azide and 0.5% bovine serum albumin (FACS buffer) for cell staining or DM for culture experiments.
Proliferation assays
Cultures were established in flat-bottom 96-well plates with PBMC at 2 × 10 5 , CD4 + at 2 × 10 5 , CD8 + at 10 5 and B cells at 7 × 10 4 per well. IFN-γ activated (100 ng/mL), irradiated (30 Gy) PTEC, at a concentration of 2.5 × 10 4 per 100 μL DM, were seeded into appropriate wells 18 h before the start of cultures. Where indicated, PD-L1 Ab at 10 μg/mL was added to wells for 3 h prior to culture, at 37°C. DM was replaced with RPMI 1640 containing 2 mM glutamine, 10 mM HEPES (N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid), 1 mM pyruvate, 0.1 mM nonessential amino acids and 10% FCS (complete media, CM) prior to the addition of immune responder cells. Cultures were established in triplicate with the following stimulator concentrations: phytohaemagglutinin (PHA) 10 μg/mL, pokeweed mitogen (PWM) 50 μg/mL, tetanus toxoid (TT) 10 μg/mL, keyhole limpet haemocyanin (KLH) 50 μg/mL, F(ab′) 2 goat anti-human IgM (αIgM) 13 μg/mL, mouse anti-human CD3 clone CLB-T3/4.E (αCD3) 0.5 μg/mL and mouse anti-human CD28 clone CLB-CD28/1 (αCD28) 0.1 μg/mL. Cultures containing PHA, αCD3 and αCD3/28 were incubated for 3 days, PWM and αIgM for 4 days and TT and KLH for 5 days at 37°C in 5% CO 2 . Proliferation was assessed by the addition of 1 μCi 3 H-thymidine/well for the last 8 h of culture, and cells were harvested using a Skatron Cell Harvester. Results are expressed as a stimulation index (SI), obtained by dividing means of triplicate test wells by means of relevant triplicate no stimulation control wells.
Cytokine analysis and cell activation markers
For cytokine and surface antigen studies, supernatants and cells were harvested from duplicate 96-well cultures, at the same time points as the proliferation plates. Samples from triplicate wells were pooled for analysis. IL-2, IL-4, IL-10 and tumour necrosis factor-alpha (TNF-α) were measured using the Human Cytometric Bead Array (BD Biosciences, Pharmingen), and IFN-γ was measured using an IFN-γ-specific ELISA (Biolegend) according to the manufacturer's instructions. Up-regulation of T cell activation markers CD25 and CD69 and B cell activation markers CD38 and CD138 were analysed with direct immunoflourescent staining with specific Ab, along with dual staining for CD4, CD8 and CD20.
Flow cytometry PTEC and stimulated lymphocytes were analysed with direct immunoflourescent staining with specific Ab for 20 min at 4°C in FACS buffer, washed once in PBS and re-suspended in FACS buffer. For regulatory T cells (Tregs), lymphocytes were first surface stained for CD4, CD25 and CD127 then fixed/perm stained with FoxP3 Ab (Biolegend) according to the manufacturer's instructions. Cells were subjected to flow cytometry using a FACSCalibur and analysed with Cell Quest Pro software (Becton Dickinson, Mountain View, CA, USA).
Statistical analysis
Statistical comparisons between groups were performed using a paired two-tailed Student's t-test. When more than two conditions were present in each treatment group, we analysed variance using a repeated measures one-way ANOVA with a Tukey's post-test. For both, a P-value <0.05 is denoted by *, <0.005 by ** and <0.001 by ***. Data are presented as means (where applicable) ± SEM.
Results
Expression of PD-L1, CD40, MHC II and ICOS-L on PTEC
We examined the effects of IFN-α, IFN-γ, TGF-β and TNF-α on PD-L1, CD40, Class II and ICOS-L expression by primary human PTEC. As can be seen in Figure 1 , only the inflammatory cytokine IFN-γ was able to exert a major up-regulation of PD-L1 [5-15 fold, mean = 9 (n = 11)] and Class II [2-19 fold, mean = 9.8 (n = 9)] expression on these cells. However, IFN-γ had little effect on ICOS-L and CD40 expression on PTEC. IFN-α, TGF-β and TNF-α were all able to induce some increase in PD-L1 expression, though this was much lower than that seen in response to IFN-γ. The effect of these cytokines on ICOS-L, Class II and CD40 expression was also minimal, less than a 1.5-fold increase. As Starke et al. [8] demonstrated that TGF-β downmodulates the IFN-γ up-regulation of PD-L1 on murine PTEC, we also examined the effect of these two cytokines in combination on PD-L1 and CD40 expression on primary human PTEC. We observed an additive effect on CD40 and PD-L1 expression when these two cytokines were used in combination ( Figure 1 ).
Modulation of proliferative responses by autologous PTEC
The proliferation of the T-cell population in response to PHA and/or cross-linking antibodies (Abs) was significantly decreased in the presence of activated autologous PTEC (Table 1 ). Figure 2 shows typical responses of three different donors and means of 10 separate experiments from six donors. There were some differences in the amplitude of the down-modulation between responding cell populations. PBMC were down-modulated in all co-cultures with PHA and Ab, and purified CD4 + T cells were downmodulated in all experiments except for one, in response to PHA. However, purified CD8 + T cells appear to be relatively refractory. Co-culture with activated autologous PTEC resulted in down-modulation in only six experiments in response to PHA and only three experiments in response to αCD3 alone. However, when CD8 + purified T cells were cultured with both αCD3 and αCD28, presumably reflecting optimal stimulation through the T-cell receptor (TCR), the down-modulation in the presence of PTEC occurred in all experiments.
Percentage decrease in the presence of activated PTEC ranged from 54 to 99% for PBMC, 41 to 94% for CD4 + T cells and 4 to 99% for CD8 + T cells ( Table 1) .
We then tested the effects of activated PTEC on the recall (TT) and naïve (KLH) Ag responses of CD4 + purified T cells. Both of these responses were inhibited by activated PTEC (Figure 3) , with TT responses exceding significance of P ≤ 0.05. This demonstrates that the inhibitory effect occurs in response to TCR activation, both through crosslinking Ab to the TCR and specific Ag, as well as polyclonal activation through PHA. Proliferative responses of B cells were also significantly down-regulated in the presence of activated autologous PTEC (Figure 4 ). Both the responses induced by the B-cell mitogen PWM and via signalling through the B-cell receptor with αIgM were significantly affected. In response to PWM, 8 out of 10 donors demonstrated inhibition of proliferation (range 8-94%, mean 64%), with all donors showing inhibition in response to αIgM (range 4-97%, mean 80%).
Down-modulation of immune-cell responses by activated autologous PTEC is partially mediated by PD-L1
Previous studies, using mouse models and allogeneic PTEC, have demonstrated that negative signalling can occur through PD-L1/PD1 interactions [9, 11] . We analysed this interaction by adding anti-PD-L1 blocking Ab to some co-cultures. The addition of this Ab resulted in partial amelioration of inhibition in some experiments, with fold change increases ranging from 1.02 to 3.32 for PBMC, 1.01 to 2.4 for CD4 + and 1.01 to 4.05 for CD8 + responder populations compared to the inhibition seen in the presence of PTEC without the blocking Ab (Figures 3 and 5 ).
Regulation of activation markers on immune responding cells in the presence of autologous PTEC
To determine whether activated PTEC decreased proliferative responses of autologous immune cells by modulation of their activation-maturation Ags, we monitored the expression of CD25 and CD69 on T cells and CD38 and CD138 on B cells in our co-cultures. There was no downregulation of these Ags on responding T-and B-cell populations in the presence of autologous activated PTEC. In fact, there was a significant up-regulation of CD69 on CD4 + and CD8 + T cells in response to most stimuli (Table 2 ) and a significant up-regulation of CD38 on B cells in response to PWM and αIgM ( Figure 6 ).
Immune-cell cytokine profiles in the presence of autologous PTEC
The cytokine profiles of responding immune cells varied across the cell populations and the stimuli used. As expected, optimal stimulation through the TCR with αCD3/ CD28 induced the highest expression of all cytokines stu- died. Under these conditions, the CD4 + population demonstrated the greatest cytokine profile modulation in that IFN-γ, IL-2 and IL-10 were all significantly down-regulated, TNF-α was down-regulated and IL-4 was significantly up-regulated in the presence of activated autologous PTEC. The CD8 + population demonstrated a strong down-ward trend (though not significant) for IFN-γ, IL-2, IL-10 and TNF-α and an increase in IL-4 secretion, whilst the whole PBMC population showed a significant downmodulation of IFN-γ, IL-10 and TNF-α and a significant up-regulation of IL-4 in the presence of activated autologous PTEC (Figure 7) . Cytokine profile responses induced by PHA and TT were more variable. However, PBMC cultures demonstrated significant down-regulation of IFN-γ, IL-10 and TNF-α and an up-regulation of IL-4 in the presence of PTEC when stimulated with PHA ( Supplementary  Figure 1) and a down-regulation of IFN-γ, IL-10 and TNF-α when stimulated with TT ( Supplementary Figure 2) . Cytokine production by B cells was also modulated by the presence of activated autologous PTEC. There was a 10-fold increase in TNF-α and IFN-γ production in our B cells stimulated with αIgM and co-cultured with PTEC ( Supplementary Figure 3) .
Activated PTEC do not induce increased levels of Tregs in co-culture
As Tregs are major players in down-regulating immune responses in vivo, we checked to determine whether the presence of autologous PTEC induced increased levels of these regulatory cells in our cultures. Three separate experiments with two different donors demonstrated no significant increases in FoxP3 Tregs in cultures containing the activated PTEC (Figure 8 ).
Discussion
Immune cell infiltration occurs in most inflammatory renal diseases, and the resulting perturbation of the cytokine/ chemokine milieu often leads to acute or chronic kidney disease, with disastrous clinical results. PTEC are thought to play a central role in this disease process, and previous research with mouse models and allogeneic PTEC has provided evidence that these cells may modulate immune responses in a positive or negative manner. In this study, we report, for the first time, the ability of primary human PTEC to modulate autologous immune responses.
Flow cytometry analysis demonstrated that primary human PTEC from our donors constitutively express very low levels of ICOS-L and MHC II, low levels of CD40 and moderate levels of PD-L1. Treatment with a range of inflammatory cytokines confirmed the findings of others [11, 16] that IFN-γ had the most profound effect on up-regulating both PD-L1 and MHC II expression on these cells. In vivo, IFN-γ is produced by activated T cells, which are often present in the interstitium of inflamed kidneys, and increased levels of PD-L1 on PTEC have been described from biopsies of such patients [11, 14] . TGF-β also has a central role in many renal diseases and is produced by infiltrating inflammatory cells and PTEC themselves. Other authors have reported that TGF-β down-regulated the IFN-γ induced up-regulation of PD-L1 on mouse PTEC cell lines [8, 17] . This was not the case in our studies where we observed small cumulative increases in PD-L1 expression on our human primary PTEC cultured in the presence of both IFN-γ and TGF-β. This apparent difference may be because we are working with primary human PTEC as opposed to murine PTEC cell lines. Such differences are not infrequent between human and mouse and emphasize that caution is required when translating murine research to human biology. Given that our primary PTEC express a range of surface Ags that may enable them to act as non-professional APC, we addressed the question of whether they could modulate autologous immune responses by co-culturing them with autologous immune cells under conditions which mimic immunological signalling. As expected in an out-bred human cohort, normal proliferative responses to the stimuli used in this study varied greatly between donors. However, although there were some differences in the responses of the parent PBMC versus their purified cell populations, the overall effect of the presence of activated autologous PTEC was inhibition of proliferative responses. This inhibition operated when cells were stimulated through the TCR complex using either αCD3/28 Abs or specific Ag and through TCR independent mitogenic stimulation.
To our knowledge, this is the first report of primary human PTEC inhibiting autologous proliferative T-and B-cell responses. Early research reported that allogeneic PTEC could either induce anergy and/or hypo-responsiveness in T-cell clones [18] and CD4 + T cells [19] or function as APC and activate T-cell hybridomas [9, 16] and T cells [11, 13] . Starke et al. [14] have more recently reported on the inhibitory effects of the PD-L1/PD-1 pathway on alloreactive T-cell responses. PD-L1, also known as B7-H1 or CD274, is a co-inhibitory molecule of the B7 family group and is known to provide negative signalling to both T and B cells via PD-1 [20] , which contains an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif (ITSM) in its cytoplasmic region [21, 22] . It has been suggested that the expression of PD-L1 on PTEC, and a wide range of other tissue types, play a role in maintaining peripheral tolerance [23] [24] [25] . As we observed a strong up-regulation of PD-L1, the most prominent co-inhibitory Ag on our activated PTEC, it seemed likely that this molecule would play a major role in the demonstrated proliferative-inhibition seen in our study. The addition of blocking Ab to PD-L1 in our culture system did indeed consign at least a partial role for this molecule in the observed inhibition for some donors and immune responses. However, this does not explain all the observed inhibition, and it seems likely that very complex interactions are at play in our observed autologous immuno-suppression, including presence of accessory cells and APC, optimal and sub-optimal stimulation through the TCR, differences in responding cell populations and stimulation mechanisms, overall health of our donors, genetic polymorphism, expression levels of PD-1 on activated T and B cells and alternate signalling through PD-L1 itself. In support of this, some research has indicated that PD-L1 can provide positive signals to immune response cells, possibly via interaction with an unknown receptor [26] or via the ITSM expressed on the cytoplasmic portion of PD-1 [27] [28] [29] . Our own observations have indicated that there is significant donor variability in expression levels of both PD-1 and PD-L1 on activated CD4 + and CD8 + cells (data not shown), and although our CD4 + and CD8 + responder cell populations were routinely >95% pure, they probably still contained low levels of APC, supporting T cell responses to αCD3 and PHA.
The PD-1-PD-L1 interaction is important in inducing and sustaining Treg cells [30] , and others have reported protective effects of Tregs in kidney injury, mediated through down-regulation of inflammatory Th1 cytokines [31] . However, we found no evidence of increased levels of Tregs in our cultures.
Two other non-exclusive mechanisms proposed for inhibition by PTEC, both mediated in part by PD-L1, are the regulation of maturation/activation molecules on T cells and the modulation of cytokine profiles produced by these cells. Chen et al. [11] reported an allogeneic response in which blockade of PD-L1 led to an increase in CD69 expression on human CD4 + T cells, suggesting a downregulation of this molecule by non-Ab-treated PTEC. The same group also reported similar results from CD4 + T cells activated with PHA [16] . We monitored the expression of CD25, CD69, CD38 and CD138 on our responding immune-cell populations and were unable to detect any significant down-regulation of these activation markers. In fact, the presence of activated autologous PTEC significantly increased levels of CD69 expression on CD4 + and CD8 + T-cell populations in response to both PHA and αCD3/28 and significantly increased levels of CD38 on B cells in response to PWM and αIgM. These findings argue against the possibility that PTEC inhibit autologous immune responses by preventing the maturation and activation of responding immune cells.
Numerous groups have reported cytokine modulation in the presence of allogeneic PTEC, with the most common finding an increase in IFN-γ and/or IL-2 expression when the PTEC are pre-treated with αPD-L1 [9, 11, 13, 14, 16, 32] , whilst De Haij et al. [12] described an ICOS-L-mediated up-regulation of IL-10 from T cells stimulated with αCD3 in the presence of allogeneic PTEC. We also detected significant modulation of cytokine profiles in the presence of activated autologous PTEC, suggesting a mechanism for our observed results. Our B-cell cultures containing PTEC showed strong up-regulation of IFN-γ and TNF-α in response to cross-linking of the T-cell receptor with αIgM. Although these cytokine levels are lower than those produced by T cells, these findings may still be relevant to local tissue responses as it is becoming apparent that Bcell-derived cytokines are able to exert an Ab-independent role in immune regulation [33] [34] [35] . The overall T-cell-derived cytokine pattern was of down-modulation of IFN-γ, Fig. 8 . Activated PTEC do not induce increased levels of regulatory T cells (Tregs) in immune-response cultures. Peripheral blood mononuclear cells (PBMC) and CD4 + purified T-cell cultures were established in the presence (grey bars) or absence (black bars) of activated, irradiated (30 Gy) autologous PTEC and in the presence of the same PTEC pre-treated with αPD-L1 (10 μg/mL) (white bars). Cultures were stimulated with phytohaemagglutinin (PHA) (10 μg/mL), αCD3 (0.5 μg/mL) or αCD3/CD28 (0.5/0.1 μg/mL) for 3 days and tetanus toxoid (TT) (10 μg/mL) or keyhole limpet haemocyanin (KLH) (50 μg/mL) for 5 days. Cells were harvested and surface stained for CD4, CD25 and CD127 (BD Biosciences, San Jose, CA) then fixed/perm stained with FoxP3 Ab (Biolegend) according to the manufacturer's instructions. Cells were subjected to flow cytometry using a FACSCalibur and analysed with Cell Quest Pro software (Becton Dickinson, Mountain View, CA,USA). Results are expressed as means ± 1 SEM. IL-2 and TNF-α and up-regulation of IL-4. IFN-γ, IL-2 and TNF-α are important cytokines in the induction and maintenance of T-cell responses and Th1 responses in particular. Thus, this cytokine profile, along with the increase in IL-4, indicates that the activated autologous PTEC induce a shift away from an inflammatory Th1 responder T-cell profile to a Th2 type profile in our in vitro cultures. If this is reflected in vivo, one could hypothesize that such an effect would help dampen inflammatory responses in renal injuries and macrophage activation seen within the interstitium and may also assist in the development of humoral immune responses to combat extra-cellular pathogens that frequently challenge the integrity of the urinary-renal system.
As our in vitro data indicate that activated PTEC do not affect cytokine profiles via Treg induction, the question remains whether they modulate autologous immune responses through direct T-and B-cell interaction or through modulation of professional APC function. We will investigate this question in our future donors.
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